Literature DB >> 17296374

Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach.

Ashutosh Tewari1, George Divine, Peter Chang, M Mendel Shemtov, Matthew Milowsky, David Nanus, Mani Menon.   

Abstract

PURPOSE: We performed a retrospective cohort study using propensity score analysis to calculate long-term survival in patients with prostate cancer with Gleason score 8 or greater who were treated with conservative therapy, radiation therapy and radical prostatectomy.
MATERIALS AND METHODS: Between January 1, 1980 and December 31, 1997, 3,159 patients in the Henry Ford Health System were diagnosed with clinically localized prostate cancer. Of these patients 453 had a Gleason score of 8 or greater in the biopsy specimen and they were the cohort. The end points were overall and prostate cancer specific survival. Propensity score analysis was used to more precisely compare the 3 treatments of observation, radiation and radical prostatectomy. Median patient followup was longer in the radical prostatectomy arm than in the conservative treatment and radiation therapy arms (68 months vs 52 and 54, respectively).
RESULTS: Of the 453 patients 197 (44%) were treated conservatively, 137 (30%) received radiation therapy and 119 (26%) underwent radical prostatectomy. Using propensity scoring analysis median overall survival for conservative therapy, radiation and radical prostatectomy was 5.2, 6.7 and 9.7 years, respectively. Median cancer specific survival was 7.8 years for conservative therapy and more than 14 years for radiation therapy and radical prostatectomy. The risk of cancer specific death following radical prostatectomy was 68% lower than for conservative treatment and 49% lower than for radiation therapy (p<0.001 and 0.053, respectively).
CONCLUSIONS: Survival of men with high grade prostate cancer can be improved by radical prostatectomy or radiation therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17296374     DOI: 10.1016/j.juro.2006.10.040

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  31 in total

1.  Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach.

Authors:  Joo Yong Lee; Ho Won Kang; Koon Ho Rha; Nam Hoon Cho; Young Deuk Choi; Sung Joon Hong; Kang Su Cho
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-12       Impact factor: 4.553

2.  Recommendations on screening for prostate cancer with the prostate-specific antigen test.

Authors:  Neil Bell; Sarah Connor Gorber; Amanda Shane; Michel Joffres; Harminder Singh; James Dickinson; Elizabeth Shaw; Lesley Dunfield; Marcello Tonelli
Journal:  CMAJ       Date:  2014-10-27       Impact factor: 8.262

3.  Radical prostatectomy is the most cost-effective primary treatment modality for men diagnosed with high-risk prostate cancer.

Authors:  Yves Fradet
Journal:  Can Urol Assoc J       Date:  2012-10       Impact factor: 1.862

4.  Is it time to reevaluate definitive therapy in prostate cancer?

Authors:  Ravi A Madan; Avni A Shah; William L Dahut
Journal:  J Natl Cancer Inst       Date:  2013-04-24       Impact factor: 13.506

Review 5.  The status of surgery in the management of high-risk prostate cancer.

Authors:  Christian Bach; Sailaja Pisipati; Datesh Daneshwar; Mark Wright; Edward Rowe; David Gillatt; Raj Persad; Anthony Koupparis
Journal:  Nat Rev Urol       Date:  2014-05-13       Impact factor: 14.432

6.  Primary radiotherapy vs conservative management for localized prostate cancer--a population-based study.

Authors:  G L Lu-Yao; S Kim; D F Moore; W Shih; Y Lin; R S DiPaola; S Shen; A Zietman; S-L Yao
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-06-23       Impact factor: 5.554

7.  Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation.

Authors:  Amol K Narang; Carol Gergis; Scott P Robertson; Pei He; Ashwin N Ram; Todd R McNutt; Emily Griffith; Theodore A DeWeese; Stephanie Honig; Harleen Singh; Danny Y Song; Phuoc T Tran; Theodore L DeWeese
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-10-31       Impact factor: 7.038

8.  [Therapy choices of German urologists and radio-oncologists if personally diagnosed with localized prostate cancer].

Authors:  R Gillitzer; C Hampel; C Thomas; F Schmidt; S W Melchior; S Pahernik; H Schmidberger; J W Thüroff
Journal:  Urologe A       Date:  2009-04       Impact factor: 0.639

Review 9.  A review of high-risk prostate cancer and the role of neo-adjuvant and adjuvant therapies.

Authors:  Joshua R Gonzalez; Melissa A Laudano; Tara R McCann; James M McKiernan; Mitchell C Benson
Journal:  World J Urol       Date:  2008-09-02       Impact factor: 4.226

10.  Substratification of high-risk localised prostate cancer treated by radical prostatectomy.

Authors:  Michele Lodde; François Harel; Louis Lacombe; Yves Fradet
Journal:  World J Urol       Date:  2008-03-28       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.